@article{3d1416cbbe414f469582bb5058cf748c,
title = "Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?",
abstract = "The distinction between chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with isolated Hodgkin/Reed–Sternberg cells (CLL-HRS; background milieu with a paucity of inflammatory cells) and overt transformation to classic Hodgkin lymphoma (CLL-HL; mixed inflammatory background) is incompletely understood. This retrospective study examined the clinicopathologic features of CLL-HRS (n = 15) and CLL-HL (n = 31) patients seen over the past three decades from a single institution. The phenotypic features of Reed–Sternberg cells in both groups were similar, including expression of CD30, CD15, and PAX5, as well as EBV status. However, a spectrum of background CLL/SLL infiltration amongst the HRS cells was noted on pathologic review, and four patients had both diagnoses, either concurrently or in succession. The median overall survival (OS) of patients with CLL-HRS was 17.5 months compared to 33.5 months for patients with CLL-HL (P = 0.24). Among patients with CLL-HRS, those who received Hodgkin-directed therapy had a significantly longer median OS (57 months) compared to those who received CLL-directed therapy (8.4 months, P = 0.02). Our clinical and pathologic findings suggest a biologic continuum between CLL-HRS and CLL-HL and indicate that CLL-HRS patients may benefit from Hodgkin-directed therapy.",
author = "King, {Rebecca L.} and Alia Gupta and Kurtin, {Paul J.} and Wei Ding and Call, {Timothy G.} and Rabe, {Kari G.} and Kenderian, {Saad S.} and Leis, {Jose F.} and Yucai Wang and Schwager, {Susan M.} and Slager, {Susan L.} and Kay, {Neil E.} and Amber Koehler and Ansell, {Stephen M.} and Inwards, {David J.} and Habermann, {Thomas M.} and Min Shi and Hanson, {Curtis A.} and Howard, {Matthew T.} and Parikh, {Sameer A.}",
note = "Funding Information: Funding was obtained through the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. The study was also supported in part by the Henry J. Predolin Foundation. The results of this study were presented at the USCAP Conference held virtually in March 2021. Funding Information: SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator (these funds are unrelated to the work presented in this manuscript). Sameer A. Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). NEK: Research funding from Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. He is on a data safety monitoring committee for Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, MorphoSys, Rigel Pharmaceuticals, and Juno Therapeutics. He is on an advisory Board for AstraZeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. WD: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). YW: Research funding (to the institution) from Incyte, InnoCare, Novartis, and Genentech. SSK: patents and royalties in the field of CART cell therapy from Novartis, Humanigen, Mettaforge, and Morphosys. Research Funding: Novartis, Kite/Gilead, Juno/BMS, Humanigen, Mor-phosys, Lentigen, Tolero, Sunesis, and LeahLabs. Advisory Board: Kite, Juno, and Humanigen. Data Safety Monitoring Board: Humanigen. TMH: is on data monitoring committees for Seagen and Tess Therapeutics. TMH is a member of the Scientific advisory boards for Lilly, Morphosys, and Incyte. TMH receives no personal income from these activities. RLK: Research funding (to the institution) from Bristol-Myers Squibb/Celgene. The remaining authors have no conflicts of interest to declare relative to this work. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = jan,
doi = "10.1038/s41408-022-00616-6",
language = "English (US)",
volume = "12",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "1",
}